Immunocore Holdings plc
Tremor tracks 4 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- IMCRImmunocore Ltd0Calm
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Running, no new patientsPhase 1/2410 patientsMain results: Oct 2026 - IMCRImmunocore Ltd0Calm
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Signing up patientsPhase 3680 patientsMain results: Oct 16, 2027 - IMCRImmunocore Ltd0Calm
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Signing up patientsPhase 3540 patientsMain results: Mar 2028 - IMCRImmunocore Ltd0Calm
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Signing up patientsPhase 1/2600 patientsMain results: Nov 30, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.